Clinical Pharmacology of Commercially Available THC-infused beverages

The Department of Cannabis Control in California has awarded a Non-IT Services agreement to the Regents of the University of California, San Francisco for clinical pharmacology research on commercially available tetrahydrocannabinol (THC)-infused beverages. The contract, effective August 20, 2026, through August 19, 2028, carries a total contract value of $1,975,523.03. This agreement falls under the classification of services agreements between governmental entities and public universities, leveraging the university's research capabilities to support the state's regulatory framework for cannabis products.

The single line item deliverable encompasses the completion of clinical pharmacology analysis on THC-infused beverages currently available in the commercial market. The research initiative, valued at $1,975,523.03, is designed to generate empirical data and scientific findings that will inform the Department of Cannabis Control's regulatory policies and oversight activities. The two-year performance period provides a defined timeline for the Regents of the University of California, San Francisco to conduct and complete the comprehensive pharmacological assessment.